What is ASP Isotopes' operating income?

ASP Isotopes' total operating income in 2025 was -$59.91 million, based on the following breakdown: Total Gross Profit: $3.41 million Total Operating Expenses: $63.31 million

ASP Isotopes (ASPI) Financials

$2.21 +0.14 (+6.76%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$2.26 +0.04 (+2.04%)

As of 04:23 AM Eastern

Compare

Annual Income Statements for ASP Isotopes

This table shows ASP Isotopes' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-4.95	-16	-35	-175
Consolidated Net Income / (Loss)	-4.95	-16	-32	-160
Net Income / (Loss) Continuing Operations	-4.95	-16	-32	-160
Total Pre-Tax Income	-4.95	-16	-32	-160
Total Operating Income	-5.10	-16	-26	-60
Total Gross Profit	0.00	0.14	1.60	3.41
Total Revenue	0.00	0.43	4.14	24
Operating Revenue	0.00	0.43	4.14	24
Total Cost of Revenue	0.00	0.29	2.55	20
Operating Cost of Revenue	0.00	0.29	2.55	20
Total Operating Expenses	5.10	16	28	63
Selling, General & Admin Expense	3.83	15	25	48
Research & Development Expense	1.27	0.76	3.14	15
Total Other Income / (Expense), net	0.15	-0.26	-5.96	-100
Interest Expense	0.00	0.12	0.26	0.58
Interest & Investment Income	0.00	0.01	1.24	6.79
Other Income / (Expense), net	0.15	-0.15	-6.94	-106
Income Tax Expense	0.00	-0.01	0.11	0.28
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-0.01	-0.09	15
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	0.00
Basic Earnings per Share	-	($0.49)	($0.63)	($2.11)
Weighted Average Basic Shares Outstanding	26.79M	33.07M	55.67M	83.01M
Diluted Earnings per Share	-	($0.49)	($0.63)	($2.11)
Weighted Average Diluted Shares Outstanding	26.79M	33.07M	55.67M	83.01M

This table shows ASP Isotopes' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-4.16	-6.95	-12	-7.27	-9.18	-8.45	-75	-13	-79	-6.88	-34
Consolidated Net Income / (Loss)	-4.17	-6.96	-8.88	-7.36	-9.22	-8.46	-75	-13	-63	-7.12	-34
Net Income / (Loss) Continuing Operations	-4.17	-6.96	-8.88	-7.36	-9.13	-8.46	-75	-13	-63	-27	-34
Total Pre-Tax Income	-4.18	-7.01	-8.87	-7.36	-9.07	-8.53	-75	-13	-63	-27	-34
Total Operating Income	-4.02	-5.81	-7.46	-5.43	-7.65	-7.95	-12	-15	-25	-25	-34
Total Gross Profit	0.14	0.28	0.42	0.29	0.61	0.33	0.57	0.42	2.08	1.67	1.48
Total Revenue	0.43	0.84	1.02	1.09	1.19	1.10	1.20	4.89	17	4.18	5.12
Operating Revenue	0.43	0.84	1.02	1.09	1.19	1.10	1.20	4.89	17	4.18	5.12
Total Cost of Revenue	0.29	0.56	0.60	0.79	0.59	0.78	0.63	4.47	15	2.51	3.64
Operating Cost of Revenue	0.29	0.56	0.60	0.79	0.59	0.78	0.63	4.47	15	2.51	3.64
Total Operating Expenses	4.16	6.09	7.88	5.73	8.25	8.28	13	15	27	27	36
Selling, General & Admin Expense	4.10	5.88	7.41	4.69	6.84	6.75	12	12	18	21	29
Research & Development Expense	0.07	0.22	0.47	1.03	1.42	1.53	0.88	3.10	9.57	5.26	6.82
Total Other Income / (Expense), net	-0.15	-1.20	-1.41	-1.93	-1.42	-0.58	-63	2.15	-38	-1.85	0.11
Interest Expense	0.12	0.01	0.07	0.09	0.09	0.09	0.08	0.15	0.26	1.73	1.77
Interest & Investment Income	0.00	0.01	0.04	0.60	0.58	0.51	0.93	1.84	3.51	3.05	2.71
Other Income / (Expense), net	-0.04	-1.20	-1.38	-2.44	-1.92	-1.01	-64	0.45	-41	-3.17	-0.83
Income Tax Expense	-0.01	-0.05	0.01	-0.01	0.06	-0.07	0.10	0.07	0.18	-0.03	-0.10
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	0.00	0.00	-	-	20	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.01	-0.02	0.05	-0.08	-0.04	-0.02	-0.10	-0.02	15	-0.24	-0.41
Basic Earnings per Share	-	($0.16)	($0.24)	($0.12)	-	($0.12)	($1.03)	($0.15)	($0.81)	($0.06)	($0.27)
Weighted Average Basic Shares Outstanding	33.07M	44.56M	49.14M	61.53M	55.67M	69.48M	73.01M	88.55M	83.01M	121.00M	122.72M
Diluted Earnings per Share	-	($0.16)	($0.24)	($0.12)	-	($0.12)	($1.03)	($0.15)	($0.81)	($0.06)	($0.27)
Weighted Average Diluted Shares Outstanding	33.07M	44.56M	49.14M	61.53M	55.67M	69.48M	73.01M	88.55M	83.01M	121.00M	122.72M
Weighted Average Basic & Diluted Shares Outstanding	33.07M	44.56M	49.14M	71.39M	72.07M	75.06M	91.91M	110.84M	0.00	125.90M	153.31M

This table details how cash moves in and out of ASP Isotopes' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-0.77	5.52	54	223
Net Cash From Operating Activities	-2.94	-5.41	-17	-38
Net Cash From Continuing Operating Activities	-2.94	-5.41	-17	-38
Net Income / (Loss) Continuing Operations	-4.95	-16	-32	-160
Consolidated Net Income / (Loss)	-4.95	-16	-32	-160
Depreciation Expense	0.00	0.04	0.47	1.91
Non-Cash Adjustments To Reconcile Net Income	1.93	9.58	18	124
Changes in Operating Assets and Liabilities, net	0.07	1.26	-2.77	-3.70
Net Cash From Investing Activities	-4.47	-2.45	-11	-111
Net Cash From Continuing Investing Activities	-4.47	-2.45	-11	-111
Purchase of Property, Plant & Equipment	-4.47	-2.33	-11	-9.65
Acquisitions	0.00	-0.12	0.00	4.57
Purchase of Investments	-	-	0.00	-76
Other Investing Activities, net	-	0.00	0.00	-30
Net Cash From Financing Activities	6.64	13	83	372
Net Cash From Continuing Financing Activities	6.64	13	83	372
Repayment of Debt	0.00	-0.70	-0.61	-16
Repurchase of Common Equity	-1.47	-0.56	-3.65	-18
Payment of Dividends	-	-	-	0.00
Issuance of Debt	0.00	0.53	26	60
Issuance of Common Equity	8.12	14	53	341
Other Financing Activities, net	-0.01	-0.01	7.27	4.14
Cash Income Taxes Paid	-	-	0.00	0.08

This table details how cash moves in and out of ASP Isotopes' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	5.57	16	6.53	23	11	-5.75	11	46	171	-72	14
Net Cash From Operating Activities	-2.06	-2.97	-5.12	-4.84	-3.76	-3.17	-7.90	-8.86	-18	-18	-23
Net Cash From Continuing Operating Activities	-2.06	-2.97	-0.60	-7.30	-3.76	-3.17	-7.90	-8.86	-18	-17	-23
Net Income / (Loss) Continuing Operations	-4.17	-6.96	-8.88	-7.36	-9.22	-8.46	-75	-13	-63	-7.37	-34
Consolidated Net Income / (Loss)	-4.17	-6.96	-8.88	-7.36	-9.22	-8.46	-75	-13	-63	-7.12	-34
Depreciation Expense	0.04	0.10	0.15	0.18	0.05	0.15	0.53	0.30	0.94	3.06	1.20
Non-Cash Adjustments To Reconcile Net Income	2.16	3.56	5.88	5.91	4.65	3.30	69	3.72	48	-6.10	3.63
Changes in Operating Assets and Liabilities, net	-0.09	0.33	2.36	-6.04	0.76	1.84	-1.81	0.02	-3.85	-6.22	5.83
Net Cash From Investing Activities	-1.26	-1.25	-2.62	-4.48	-3.02	-2.36	-32	-1.50	-75	-97	40
Net Cash From Continuing Investing Activities	-1.26	-1.25	-2.62	-4.48	-3.02	-2.36	-32	-1.50	-75	-97	40
Purchase of Property, Plant & Equipment	-1.14	-1.25	-2.62	-4.48	-1.32	-2.36	-1.80	-3.15	-2.40	-6.14	-4.09
Purchase of Investments	-	-	-	-	-	0.00	-	-	-71	-45	-4.07
Other Investing Activities, net	-	0.00	-	-	-	0.00	-30	-	0.03	0.16	0.12
Net Cash From Financing Activities	8.89	20	12	32	18	-0.23	51	57	264	43	-2.50
Net Cash From Continuing Financing Activities	8.89	20	12	32	18	-0.23	51	57	264	-2.72	-2.50
Repayment of Debt	-0.70	-0.26	-0.18	-	-0.17	-0.25	-0.55	-2.58	-13	-2.09	-1.63
Other Financing Activities, net	-0.01	-0.02	1.48	5.57	0.23	-0.02	4.79	-0.37	-0.27	-0.68	-0.87

This table presents ASP Isotopes' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	12	28	94	498
Total Current Assets	3.30	11	66	400
Cash & Equivalents	2.39	7.91	62	280
Restricted Cash	-	-	-	0.00
Short-Term Investments	-	-	0.00	48
Note & Lease Receivable	-	-	0.00	32
Accounts Receivable	0.00	0.22	0.71	1.08
Inventories, net	-	0.00	0.07	1.10
Prepaid Expenses	0.91	1.66	3.05	4.95
Other Current Assets	0.00	0.72	0.03	1.78
Other Current Nonoperating Assets	-	-	-	32
Plant, Property, & Equipment, net	8.20	11	22	33
Total Noncurrent Assets	0.99	6.32	6.25	65
Long-Term Investments	-	-	0.00	5.58
Noncurrent Note & Lease Receivables	-	-	0.00	0.43
Goodwill	0.00	3.27	3.17	5.18
Intangible Assets	-	-	0.00	0.41
Noncurrent Deferred & Refundable Income Taxes	-	0.00	0.03	0.00
Other Noncurrent Operating Assets	0.99	3.05	3.05	2.33
Other Noncurrent Nonoperating Assets	-	-	-	51
Total Liabilities & Shareholders' Equity	12	28	94	498
Total Liabilities	2.68	8.71	43	235
Total Current Liabilities	1.94	5.67	7.06	33
Short-Term Debt	0.03	0.47	0.94	0.58
Accounts Payable	1.35	1.11	1.02	3.81
Accrued Expenses	0.36	1.31	2.28	4.41
Current Deferred Revenue	0.00	0.88	0.88	0.88
Other Current Liabilities	0.19	1.90	1.94	1.21
Other Current Nonoperating Liabilities	-	-	-	22
Total Noncurrent Liabilities	0.74	3.04	36	202
Long-Term Debt	-	0.00	33	201
Noncurrent Deferred Revenue	-	-	-	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	0.11	0.00	0.00
Other Noncurrent Operating Liabilities	0.74	2.93	2.69	1.53
Other Noncurrent Nonoperating Liabilities	-	-	-	0.10
Commitments & Contingencies	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	9.82	19	51	263
Total Preferred & Common Equity	9.82	16	48	204
Preferred Stock	0.00	0.00	0.00	0.00
Total Common Equity	9.82	16	48	204
Common Stock	17	41	106	433
Retained Earnings	-7.55	-24	-56	-231
Treasury Stock	-	-	-	0.00
Accumulated Other Comprehensive Income / (Loss)	0.26	-0.92	-2.16	2.54
Noncontrolling Interest	0.00	2.53	3.27	59

This table presents ASP Isotopes' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	12	45	55	84	91	136	226	588	572
Total Current Assets	2.73	26	32	56	59	102	174	309	272
Cash & Equivalents	2.29	24	28	52	56	68	114	207	220
Restricted Cash	-	-	-	-	-	-	-	2.77	4.12
Short-Term Investments	-	-	-	-	-	-	-	83	35
Note & Lease Receivable	-	-	-	-	-	30	31	0.00	0.00
Accounts Receivable	-	0.35	0.52	0.56	0.69	0.65	17	2.39	3.04
Inventories, net	-	-	-	0.08	0.34	1.05	1.37	1.37	1.53
Prepaid Expenses	0.44	1.93	3.25	3.87	2.03	1.83	10	8.73	7.92
Other Current Assets	-	0.00	0.05	0.00	0.00	0.02	0.02	2.96	0.66
Other Current Nonoperating Assets	-	-	-	-	-	-	-	0.00	0.00
Plant, Property, & Equipment, net	8.35	14	18	23	25	28	31	92	42
Total Noncurrent Assets	0.80	4.85	4.91	5.05	6.47	6.73	21	187	258
Long-Term Investments	-	-	-	-	-	-	6.32	40	44
Noncurrent Note & Lease Receivables	-	-	-	-	-	0.38	0.41	3.91	4.04
Goodwill	-	3.17	3.29	3.46	3.26	3.36	6.85	6.39	6.47
Intangible Assets	-	-	-	-	-	-	1.19	0.68	0.63
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	0.11	0.03	0.07	0.07	0.00
Other Noncurrent Operating Assets	0.80	1.68	1.63	1.59	3.09	2.95	6.07	136	202
Other Noncurrent Nonoperating Assets	-	-	-	-	-	-	-	0.00	0.00
Total Liabilities & Shareholders' Equity	12	45	55	84	91	136	226	588	572
Total Liabilities	3.23	32	40	42	45	108	129	289	297
Total Current Liabilities	2.60	7.33	8.01	7.43	8.18	6.90	28	70	70
Short-Term Debt	0.03	0.21	0.03	0.03	0.77	0.34	12	53	55
Accounts Payable	0.40	2.22	2.43	1.80	2.05	2.60	3.42	6.87	5.70
Accrued Expenses	1.09	1.77	2.46	1.76	3.05	1.79	3.66	7.90	8.07
Current Deferred Revenue	0.88	0.88	0.88	0.88	0.88	0.88	0.88	0.88	0.88
Other Current Liabilities	0.19	2.25	2.21	2.95	1.43	1.29	7.96	1.46	1.11
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	0.00	0.00
Total Noncurrent Liabilities	0.63	25	32	35	37	101	101	218	227
Long-Term Debt	-	22	29	32	36	98	100	205	209
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	0.82	0.91
Noncurrent Deferred & Payable Income Tax Liabilities	-	0.06	0.07	0.08	-	-	0.31	5.98	8.01
Other Noncurrent Operating Liabilities	0.63	2.95	3.23	2.83	1.11	2.55	1.14	6.53	9.44
Other Noncurrent Nonoperating Liabilities	-	-	-	-	-	-	-	0.00	0.00
Commitments & Contingencies	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	8.64	13	14	42	46	28	97	299	275
Total Preferred & Common Equity	8.64	11	11	39	43	25	74	289	265
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	8.64	11	11	39	43	25	74	289	265
Common Stock	30	43	51	85	108	165	226	530	535
Retained Earnings	-20	-31	-40	-47	-65	-140	-153	-239	-273
Treasury Stock	-	-	-	-	-	-	-	0.00	-0.00
Accumulated Other Comprehensive Income / (Loss)	-1.29	-1.46	-0.70	0.60	-0.99	0.03	0.95	-2.66	2.67
Noncontrolling Interest	-	2.51	3.35	3.32	3.21	3.08	23	10	10

This table displays calculated financial ratios and metrics derived from ASP Isotopes' official financial filings.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	110,840,122.00
DEI Adjusted Shares Outstanding	-	-	-	110,840,122.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-1.58
Growth Metrics	-	-	-	-
Revenue Growth	0.00%	0.00%	857.04%	475.51%
EBITDA Growth	0.00%	-226.43%	-103.18%	-399.28%
EBIT Growth	0.00%	-227.18%	-105.62%	-397.96%
NOPAT Growth	0.00%	-214.61%	-64.28%	-127.32%
Net Income Growth	0.00%	-229.50%	-98.98%	-392.99%
EPS Growth	0.00%	0.00%	-28.57%	-234.92%
Operating Cash Flow Growth	0.00%	-84.10%	-208.47%	-126.28%
Free Cash Flow Firm Growth	0.00%	0.00%	-102.53%	-267.31%
Invested Capital Growth	0.00%	52.67%	107.57%	299.56%
Revenue Q/Q Growth	0.00%	0.00%	22.49%	184.48%
EBITDA Q/Q Growth	0.00%	-1,667,112.69%	-20.10%	-51.83%
EBIT Q/Q Growth	0.00%	0.00%	-19.80%	-52.16%
NOPAT Q/Q Growth	0.00%	0.00%	-15.95%	-40.84%
Net Income Q/Q Growth	0.00%	0.00%	-18.45%	-51.18%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-49.65%
Operating Cash Flow Q/Q Growth	0.00%	-28.34%	-11.36%	-59.48%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	3.38%	-17.76%
Invested Capital Q/Q Growth	0.00%	78.39%	6.28%	7.07%
Profitability Metrics	-	-	-	-
Gross Margin	0.00%	32.09%	38.60%	14.28%
EBITDA Margin	0.00%	-3,730.34%	-791.94%	-687.09%
Operating Margin	0.00%	-3,704.63%	-635.91%	-251.20%
EBIT Margin	0.00%	-3,738.99%	-803.31%	-695.11%
Profit (Net Income) Margin	0.00%	-3,762.85%	-782.36%	-670.23%
Tax Burden Percent	100.00%	99.96%	100.34%	100.18%
Interest Burden Percent	99.93%	100.68%	97.06%	96.25%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-119.11%	-105.29%	-70.99%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-15.68%	-25.33%	49.37%
Return on Net Nonoperating Assets (RNNOA)	0.00%	5.36%	12.65%	-30.80%
Return on Equity (ROE)	-100.74%	-113.75%	-92.64%	-101.79%
Cash Return on Invested Capital (CROIC)	0.00%	-160.81%	-175.24%	-190.92%
Operating Return on Assets (OROA)	0.00%	-80.88%	-54.62%	-55.97%
Return on Assets (ROA)	0.00%	-81.39%	-53.20%	-53.97%
Return on Common Equity (ROCE)	-100.74%	-103.69%	-84.96%	-81.69%
Return on Equity Simple (ROE_SIMPLE)	-50.37%	-99.99%	-67.69%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.57	-11	-18	-42
NOPAT Margin	0.00%	-2,593.24%	-445.14%	-175.84%
Net Nonoperating Expense Percent (NNEP)	-58.41%	-103.43%	-79.96%	-120.36%
Return On Investment Capital (ROIC_SIMPLE)	-	-58.18%	-21.57%	-8.83%
Cost of Revenue to Revenue	0.00%	67.91%	61.40%	85.72%
SG&A Expenses to Revenue	0.00%	3,560.15%	598.77%	202.26%
R&D to Revenue	0.00%	176.57%	75.74%	63.21%
Operating Expenses to Revenue	0.00%	3,736.72%	674.51%	265.47%
Earnings before Interest and Taxes (EBIT)	-4.95	-16	-33	-166
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.95	-16	-33	-164
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	0.00	5.36	6.75	2.90
Price to Tangible Book Value (P/TBV)	0.00	6.70	7.23	3.06
Price to Revenue (P/Rev)	0.00	201.61	78.04	24.86
Price to Earnings (P/E)	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	7.23	12.65	5.12
Enterprise Value to Revenue (EV/Rev)	0.00	190.29	72.18	20.27
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	0.00	0.03	0.67	0.81
Long-Term Debt to Equity	0.00	0.00	0.65	0.76
Financial Leverage	-0.24	-0.34	-0.50	-0.62
Leverage Ratio	1.27	1.40	1.74	1.89
Compound Leverage Factor	1.27	1.41	1.69	1.82
Debt to Total Capital	0.34%	2.44%	40.18%	44.67%
Short-Term Debt to Total Capital	0.34%	2.44%	1.10%	2.71%
Long-Term Debt to Total Capital	0.00%	0.00%	39.09%	41.95%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	13.13%	3.82%	12.37%
Common Equity to Total Capital	99.66%	84.43%	56.00%	42.97%
Debt to EBITDA	-0.01	-0.03	-1.05	-1.30
Net Debt to EBITDA	0.48	0.46	0.84	1.03
Long-Term Debt to EBITDA	0.00	0.00	-1.02	-1.22
Debt to NOPAT	-0.01	-0.04	-1.86	-5.06
Net Debt to NOPAT	0.66	0.66	1.49	4.02
Long-Term Debt to NOPAT	0.00	0.00	-1.81	-4.75
Altman Z-Score	0.00	3.09	3.29	0.70
Noncontrolling Interest Sharing Ratio	0.00%	8.85%	8.29%	19.75%
Liquidity Ratios	-	-	-	-
Current Ratio	1.71	1.85	9.31	12.23
Quick Ratio	1.23	1.43	8.87	11.72
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-15	-31	-113
Operating Cash Flow to CapEx	-65.72%	-232.16%	-172.56%	-391.34%
Free Cash Flow to Firm to Interest Expense	0.00	-127.88	-118.61	-196.14
Operating Cash Flow to Interest Expense	0.00	-45.66	-64.49	-65.70
Operating Cash Flow Less CapEx to Interest Expense	0.00	-65.32	-101.87	-82.49
Efficiency Ratios	-	-	-	-
Asset Turnover	0.00	0.02	0.07	0.08
Accounts Receivable Turnover	0.00	0.00	8.98	2.57
Inventory Turnover	0.00	0.00	0.00	35.13
Fixed Asset Turnover	0.00	0.05	0.25	0.85
Accounts Payable Turnover	0.00	0.24	2.39	6.03
Days Sales Outstanding (DSO)	0.00	0.00	40.67	142.25
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	10.39
Days Payable Outstanding (DPO)	0.00	1,530.92	152.99	60.49
Cash Conversion Cycle (CCC)	0.00	-1,530.92	-112.33	92.15
Capital & Investment Metrics	-	-	-	-
Invested Capital	7.46	11	24	94
Invested Capital Turnover	0.00	0.05	0.24	0.40
Increase / (Decrease) in Invested Capital	0.00	3.93	12	71
Enterprise Value (EV)	0.00	82	299	483
Market Capitalization	0.00	87	323	593
Book Value per Share	$0.37	$0.33	$0.67	$1.84
Tangible Book Value per Share	$0.37	$0.27	$0.63	$1.75
Total Capital	9.85	19	86	475
Total Debt	0.03	0.47	34	212
Total Long-Term Debt	0.00	0.00	33	199
Net Debt	-2.36	-7.44	-28	-168
Capital Expenditures (CapEx)	4.47	2.33	9.68	9.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.99	-2.60	-2.27	47
Debt-free Net Working Capital (DFNWC)	1.40	5.31	60	380
Net Working Capital (NWC)	1.37	4.84	59	367
Net Nonoperating Expense (NNE)	1.38	5.06	14	118
Net Nonoperating Obligations (NNO)	-2.36	-7.44	-28	-168
Total Depreciation and Amortization (D&A)	0.00	0.04	0.47	1.91
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-600.77%	-54.67%	196.23%
Debt-free Net Working Capital to Revenue	0.00%	1,225.49%	1,438.74%	1,593.81%
Net Working Capital to Revenue	0.00%	1,116.86%	1,416.08%	1,539.78%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.63)	($2.11)
Adjusted Weighted Average Basic Shares Outstanding	0.00	33.07M	55.67M	83.01M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.63)	($2.11)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	33.07M	55.67M	83.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	33.07M	72.07M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-3.57	-11	-18	-42
Normalized NOPAT Margin	0.00%	-2,593.24%	-445.14%	-175.84%
Pre Tax Income Margin	0.00%	-3,764.27%	-779.67%	-669.05%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	0.00	-136.58	-128.60	-288.31
NOPAT to Interest Expense	0.00	-94.73	-71.26	-72.93
EBIT Less CapEx to Interest Expense	0.00	-156.24	-165.98	-305.10
NOPAT Less CapEx to Interest Expense	0.00	-114.39	-108.64	-89.72
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-29.63%	-3.46%	-11.25%	-11.24%

This table displays calculated financial ratios and metrics derived from ASP Isotopes' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	110,840,122.00	110,840,122.00	125,903,447.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	110,840,122.00	110,840,122.00	125,903,447.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-0.71	-0.06	-0.27
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	175.71%	31.09%	17.22%	349.53%	1,295.68%	279.31%	327.63%
EBITDA Growth	0.00%	-89.22%	-103.56%	-82.22%	-136.43%	-27.54%	-766.82%	-84.72%	-587.75%	-183.78%	55.12%
EBIT Growth	0.00%	-93.91%	-106.23%	-86.35%	-135.43%	-27.78%	-758.45%	-84.36%	-594.28%	-213.18%	53.85%
NOPAT Growth	0.00%	-56.11%	-71.53%	-37.68%	-90.10%	-36.76%	-60.49%	-175.45%	-227.14%	-212.98%	-185.70%
Net Income Growth	0.00%	-92.66%	-107.20%	-74.20%	-121.12%	-21.49%	-746.23%	-75.29%	-586.79%	15.84%	54.77%
EPS Growth	0.00%	0.00%	0.00%	14.29%	0.00%	25.00%	-329.17%	-25.00%	-636.36%	50.00%	73.79%
Operating Cash Flow Growth	-138.65%	-105.57%	-307.72%	-640.92%	-82.76%	-6.72%	-54.18%	-83.00%	-374.71%	-460.25%	-195.33%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	-114.98%	-161.00%	-33.46%	-155.81%	-288.81%	-401.75%	-941.87%	-281.53%
Invested Capital Growth	52.67%	0.00%	0.00%	248.42%	107.57%	132.27%	288.51%	296.59%	299.56%	747.08%	296.90%
Revenue Q/Q Growth	0.00%	94.07%	21.65%	6.40%	9.76%	-7.73%	8.78%	308.02%	240.72%	-74.91%	22.56%
EBITDA Q/Q Growth	4.73%	-69.15%	-27.71%	11.46%	-23.62%	7.44%	-755.59%	81.13%	-360.26%	61.81%	-35.31%
EBIT Q/Q Growth	3.88%	-72.60%	-26.12%	10.94%	-21.44%	6.32%	-747.28%	80.87%	-357.32%	57.74%	-24.85%
NOPAT Q/Q Growth	-1.94%	-44.53%	-28.25%	27.14%	-40.75%	-3.98%	-50.50%	-25.05%	-67.17%	0.53%	-37.40%
Net Income Q/Q Growth	1.24%	-13,426.27%	-27.52%	17.18%	-25.36%	8.24%	-788.23%	82.84%	-391.18%	88.76%	-377.36%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-758.33%	85.44%	-440.00%	92.59%	-350.00%
Operating Cash Flow Q/Q Growth	-214.91%	-44.39%	-72.52%	5.55%	22.32%	15.69%	-149.26%	-12.10%	-101.53%	0.51%	-31.39%
Free Cash Flow Firm Q/Q Growth	26.26%	-128.71%	-32.45%	3.76%	10.47%	-16.94%	-153.88%	-46.27%	-15.54%	-232.34%	7.03%
Invested Capital Q/Q Growth	78.39%	-0.29%	33.96%	46.23%	6.28%	11.58%	124.06%	49.27%	7.07%	216.18%	4.99%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	32.09%	33.18%	41.18%	27.03%	50.74%	29.67%	47.74%	8.65%	12.50%	39.86%	28.89%
EBITDA Margin	-929.61%	-810.25%	-850.59%	-707.83%	-797.18%	-799.72%	-6,289.94%	-290.86%	-392.91%	-598.04%	-660.26%
Operating Margin	-929.07%	-691.95%	-729.48%	-499.55%	-640.58%	-721.89%	-998.76%	-306.10%	-150.19%	-595.41%	-667.48%
EBIT Margin	-938.03%	-834.28%	-864.93%	-724.01%	-801.01%	-813.24%	-6,334.16%	-296.92%	-398.54%	-671.17%	-683.72%
Profit (Net Income) Margin	-963.04%	-828.80%	-868.77%	-676.24%	-772.36%	-768.10%	-6,271.75%	-263.70%	-380.15%	-170.36%	-663.54%
Tax Burden Percent	99.85%	99.32%	100.16%	99.89%	101.69%	99.17%	100.13%	100.57%	100.29%	26.63%	99.72%
Interest Burden Percent	102.82%	100.02%	100.29%	93.51%	94.82%	95.24%	98.89%	88.30%	95.11%	95.30%	97.32%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-29.87%	-108.59%	-154.06%	-82.62%	-106.06%	-117.95%	-86.17%	-32.51%	-42.44%	-89.82%	-98.14%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.22%	238.73%	-1,009.54%	-50.35%	-83.93%	-90.39%	-507.93%	-15.32%	4.33%	-111.54%	117.68%
Return on Net Nonoperating Assets (RNNOA)	0.76%	-30.54%	-60.17%	21.88%	41.92%	32.32%	-376.93%	3.11%	-2.70%	30.69%	-3.62%
Return on Equity (ROE)	-29.11%	-139.13%	-214.23%	-60.74%	-64.15%	-85.63%	-463.11%	-29.40%	-45.14%	-59.13%	-101.75%
Cash Return on Invested Capital (CROIC)	-160.81%	-423.45%	-395.42%	-221.91%	-175.24%	-185.29%	-180.27%	-173.34%	-190.92%	-200.81%	-166.71%
Operating Return on Assets (OROA)	-20.29%	-46.81%	-72.52%	-51.03%	-54.47%	-52.59%	-304.39%	-16.06%	-32.09%	-53.27%	-59.59%
Return on Assets (ROA)	-20.83%	-46.51%	-72.84%	-47.67%	-52.52%	-49.67%	-301.39%	-14.26%	-30.61%	-13.52%	-57.83%
Return on Common Equity (ROCE)	-26.54%	-112.33%	-164.26%	-56.76%	-58.83%	-77.29%	-393.33%	-23.92%	-36.23%	-56.86%	-97.33%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-186.77%	-220.12%	-70.74%	0.00%	-79.79%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.82	-4.07	-5.22	-3.80	-5.35	-5.57	-8.38	-10	-18	-17	-24
NOPAT Margin	-650.35%	-484.36%	-510.64%	-349.69%	-448.41%	-505.32%	-699.13%	-214.27%	-105.13%	-416.78%	-467.24%
Net Nonoperating Expense Percent (NNEP)	-27.65%	-347.31%	855.48%	-32.27%	-22.13%	-27.56%	421.76%	-17.19%	-46.77%	21.72%	-215.81%
Return On Investment Capital (ROIC_SIMPLE)	-14.59%	-	-	-	-6.26%	-6.76%	-6.61%	-5.02%	-3.69%	-3.13%	-4.45%
Cost of Revenue to Revenue	67.91%	66.82%	58.82%	72.97%	49.26%	70.33%	52.26%	91.35%	87.50%	60.14%	71.11%
SG&A Expenses to Revenue	946.11%	699.53%	724.37%	431.48%	572.71%	612.69%	973.07%	251.39%	105.26%	509.35%	563.17%
R&D to Revenue	15.05%	25.60%	46.30%	95.10%	118.61%	138.87%	73.43%	63.37%	57.43%	125.91%	133.20%
Operating Expenses to Revenue	961.16%	725.13%	770.66%	526.58%	691.32%	751.56%	1,046.50%	314.76%	162.69%	635.26%	696.37%
Earnings before Interest and Taxes (EBIT)	-4.06	-7.01	-8.84	-7.87	-9.56	-8.96	-76	-15	-66	-28	-35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.03	-6.81	-8.70	-7.70	-9.52	-8.81	-75	-14	-65	-25	-34
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.36	19.15	14.38	4.79	6.75	7.95	21.90	11.94	2.90	1.70	2.96
Price to Tangible Book Value (P/TBV)	6.70	27.40	20.51	5.26	7.23	8.61	25.26	13.39	3.06	1.74	3.04
Price to Revenue (P/Rev)	201.61	158.19	69.00	54.79	78.04	76.72	120.58	105.47	24.86	18.19	25.38
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.23	17.81	10.69	7.59	12.65	12.20	9.92	10.18	5.12	1.90	3.21
Enterprise Value to Revenue (EV/Rev)	190.29	158.85	70.83	49.93	72.18	73.06	127.98	107.16	20.27	15.76	24.41
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.03	1.71	2.03	0.76	0.67	0.80	3.48	1.16	0.81	0.86	0.96
Long-Term Debt to Equity	0.00	1.69	2.03	0.76	0.65	0.78	3.47	1.03	0.76	0.69	0.76
Financial Leverage	-0.34	-0.13	0.06	-0.43	-0.50	-0.36	0.74	-0.20	-0.62	-0.28	-0.03
Leverage Ratio	1.40	3.48	3.81	1.90	1.74	2.32	4.47	2.24	1.89	1.97	2.34
Compound Leverage Factor	1.44	3.48	3.82	1.77	1.65	2.21	4.42	1.97	1.79	1.88	2.27
Debt to Total Capital	2.44%	63.05%	66.97%	43.09%	40.18%	44.47%	77.67%	53.67%	44.67%	46.34%	48.92%
Short-Term Debt to Total Capital	2.44%	0.59%	0.07%	0.05%	1.10%	0.94%	0.27%	5.95%	2.71%	9.56%	10.13%
Long-Term Debt to Total Capital	0.00%	62.46%	66.90%	43.05%	39.09%	43.53%	77.40%	47.72%	41.95%	36.78%	38.78%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	13.13%	7.12%	7.71%	4.49%	3.82%	3.90%	2.43%	10.81%	12.37%	1.80%	1.88%
Common Equity to Total Capital	84.43%	29.84%	25.33%	52.42%	56.00%	51.62%	19.90%	35.52%	42.97%	51.86%	49.21%
Debt to EBITDA	-0.03	-1.14	-1.22	-1.16	-1.05	-1.05	-0.97	-1.04	-1.30	-1.43	-1.90
Net Debt to EBITDA	0.46	0.09	-0.04	0.72	0.84	0.56	-0.30	0.08	1.03	0.42	0.29
Long-Term Debt to EBITDA	0.00	-1.13	-1.22	-1.16	-1.02	-1.03	-0.97	-0.92	-1.22	-1.14	-1.51
Debt to NOPAT	-0.04	-1.75	-1.96	-2.00	-1.86	-1.84	-4.26	-3.76	-5.06	-4.80	-3.79
Net Debt to NOPAT	0.66	0.13	-0.06	1.24	1.49	0.97	-1.33	0.28	4.02	1.40	0.58
Long-Term Debt to NOPAT	0.00	-1.73	-1.96	-2.00	-1.81	-1.80	-4.25	-3.34	-4.75	-3.81	-3.01
Altman Z-Score	4.54	2.80	1.37	2.28	4.12	3.89	0.67	3.76	1.36	0.83	1.19
Noncontrolling Interest Sharing Ratio	8.85%	19.26%	23.33%	6.55%	8.29%	9.74%	15.07%	18.65%	19.75%	3.84%	4.35%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.85	3.57	4.00	7.55	9.31	7.21	14.72	6.14	12.23	4.39	3.87
Quick Ratio	1.43	3.31	3.59	7.02	8.87	6.92	14.30	5.74	11.72	4.16	3.67
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.75	-15	-20	-20	-18	-21	-52	-76	-88	-215	-199
Operating Cash Flow to CapEx	-180.27%	-238.43%	-195.45%	-107.93%	-284.25%	-137.27%	-439.39%	-281.35%	-744.34%	-289.39%	-570.51%
Free Cash Flow to Firm to Interest Expense	-56.91	-1,119.13	-295.87	-216.23	-207.08	-236.29	-639.13	-523.60	-339.85	-124.09	-112.44
Operating Cash Flow to Interest Expense	-17.35	-215.44	-74.19	-53.21	-44.21	-36.37	-96.59	-60.65	-68.66	-10.27	-13.15
Operating Cash Flow Less CapEx to Interest Expense	-26.98	-305.79	-112.15	-102.51	-59.77	-62.87	-118.57	-82.20	-77.88	-13.82	-15.46
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.06	0.08	0.07	0.07	0.06	0.05	0.05	0.08	0.08	0.09
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	8.98	8.42	7.87	0.93	2.57	17.46	16.72
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.86	35.13	25.92	19.59
Fixed Asset Turnover	0.05	0.00	0.00	0.22	0.25	0.22	0.20	0.31	0.85	0.46	0.88
Accounts Payable Turnover	0.24	0.00	0.00	2.05	2.39	1.29	1.11	2.47	6.03	4.98	6.07
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	40.67	43.34	46.40	391.55	142.25	20.91	21.84
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	41.18	10.39	14.08	18.63
Days Payable Outstanding (DPO)	1,530.92	0.00	0.00	178.36	152.99	282.61	330.10	147.64	60.49	73.35	60.14
Cash Conversion Cycle (CCC)	-1,530.92	0.00	0.00	-178.36	-112.33	-239.27	-283.69	285.09	92.15	-38.36	-19.68
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	11	11	15	22	24	26	59	88	94	224	235
Invested Capital Turnover	0.05	0.22	0.30	0.24	0.24	0.23	0.12	0.15	0.40	0.22	0.21
Increase / (Decrease) in Invested Capital	3.93	11	15	16	12	15	44	66	71	197	176
Enterprise Value (EV)	82	202	163	169	299	322	586	898	483	424	753
Market Capitalization	87	201	158	185	323	338	552	884	593	490	783
Book Value per Share	$0.33	$0.22	$0.21	$0.58	$0.67	$0.60	$0.34	$0.81	$1.84	$2.61	$2.10
Tangible Book Value per Share	$0.27	$0.15	$0.15	$0.53	$0.63	$0.55	$0.29	$0.72	$1.75	$2.54	$2.05
Total Capital	19	35	43	74	86	82	127	209	475	557	538
Total Debt	0.47	22	29	32	34	37	98	112	212	258	263
Total Long-Term Debt	0.00	22	29	32	33	36	98	100	199	205	209
Net Debt	-7.44	-1.67	0.86	-20	-28	-19	31	-8.35	-168	-76	-40
Capital Expenditures (CapEx)	1.14	1.25	2.62	4.48	1.32	2.31	1.80	3.15	2.40	6.14	4.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.60	-4.84	-4.17	-2.87	-2.27	-4.35	27	44	47	-1.64	-2.62
Debt-free Net Working Capital (DFNWC)	5.31	19	24	49	60	52	95	158	380	292	256
Net Working Capital (NWC)	4.84	19	24	49	59	51	95	146	367	238	202
Net Nonoperating Expense (NNE)	1.35	2.89	3.66	3.55	3.87	2.89	67	2.42	46	-10	10
Net Nonoperating Obligations (NNO)	-7.44	-1.67	0.86	-20	-28	-19	31	-8.35	-168	-76	-40
Total Depreciation and Amortization (D&A)	0.04	0.20	0.15	0.18	0.05	0.15	0.53	0.30	0.94	3.06	1.20
Debt-free, Cash-free Net Working Capital to Revenue	-600.77%	-380.09%	-181.67%	-84.97%	-54.67%	-98.71%	596.92%	527.00%	196.23%	-6.11%	-8.49%
Debt-free Net Working Capital to Revenue	1,225.49%	1,496.08%	1,049.44%	1,439.29%	1,438.74%	1,171.66%	2,074.14%	1,886.15%	1,593.81%	1,083.07%	831.06%
Net Working Capital to Revenue	1,116.86%	1,479.86%	1,048.06%	1,438.31%	1,416.08%	1,154.07%	2,066.67%	1,738.22%	1,539.78%	885.26%	654.37%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($0.12)	$0.00	($0.12)	($1.03)	($0.15)	($0.81)	($0.06)	($0.27)
Adjusted Weighted Average Basic Shares Outstanding	33.07M	51.76M	66.69M	61.53M	55.67M	69.48M	73.01M	88.55M	83.01M	121.00M	122.72M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.12)	$0.00	($0.12)	($1.03)	($0.15)	($0.81)	($0.06)	($0.27)
Adjusted Weighted Average Diluted Shares Outstanding	33.07M	51.76M	66.69M	61.53M	55.67M	69.48M	73.01M	88.55M	83.01M	121.00M	122.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.07M	44.56M	49.14M	71.39M	72.07M	75.06M	91.91M	110.84M	0.00	125.90M	153.31M
Normalized Net Operating Profit after Tax (NOPAT)	-2.82	-4.07	-5.22	-3.80	-5.35	-5.57	-8.38	-10	-18	-17	-24
Normalized NOPAT Margin	-650.35%	-484.36%	-510.64%	-349.69%	-448.41%	-505.32%	-699.13%	-214.27%	-105.13%	-416.78%	-467.24%
Pre Tax Income Margin	-964.46%	-834.47%	-867.42%	-677.01%	-759.49%	-774.52%	-6,263.80%	-262.19%	-379.04%	-639.64%	-665.43%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-34.26	-508.48	-128.00	-86.57	-112.46	-102.80	-927.90	-99.40	-255.37	-16.23	-19.74
NOPAT to Interest Expense	-23.76	-295.21	-75.57	-41.81	-62.96	-63.87	-102.42	-71.73	-67.36	-10.08	-13.49
EBIT Less CapEx to Interest Expense	-43.89	-598.83	-165.96	-135.87	-128.02	-129.29	-949.88	-120.96	-264.60	-19.78	-22.05
NOPAT Less CapEx to Interest Expense	-33.38	-385.57	-113.53	-91.11	-78.51	-90.37	-124.40	-93.29	-76.59	-13.63	-15.80
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3.46%	0.00%	-0.24%	-8.22%	-11.25%	0.00%	-6.83%	-7.93%	-11.24%	0.00%	-12.55%

Financials Breakdown Chart

Key Financial Trends

ASP Isotopes’ second-quarter 2026 results show strong revenue growth, but the company remains deeply unprofitable and cash-flow negative. Revenue reached $5.1 million, up 22.6% from the first quarter and more than quadruple the $1.2 million reported in the restated second quarter of 2025. However, revenue remains small relative to the company’s cost structure, and ASP Isotopes continues to rely on its balance sheet and external financing to fund operations.

Revenue momentum is improving. Quarterly revenue increased from $840,000 in the first quarter of 2024 to $5.1 million in the second quarter of 2026. The latest quarter also represented sequential growth from $4.2 million in Q1 2026.
Liquidity has improved substantially. ASP Isotopes ended Q2 2026 with $219.6 million of cash, $35.3 million of short-term investments and $4.1 million of restricted cash. Total current assets were $272.2 million versus $70.3 million of current liabilities.
Gross profit remains positive. The company generated $1.5 million of gross profit in Q2 2026, compared with $1.7 million in Q1 2026 and only $572,000 in Q2 2025.
Interest income is helping offset financing costs. Interest and investment income was $2.7 million in Q2 2026, exceeding the $1.8 million interest expense and providing some support for cash balances.
Investment activity has increased significantly. Purchases of property, plant and equipment totaled $4.1 million in Q2 2026, while purchases of investments totaled $4.1 million. These outlays may support future expansion, but their financial return is not yet evident in profitability.
The balance sheet has expanded rapidly through financing and investment activity. Total assets increased from $90.9 million in Q1 2025 to $572.0 million in Q2 2026, although the latest quarter was down from $587.7 million in Q1 2026. Investors should monitor whether the newer assets generate sufficient revenue and cash flow.
Operating losses are widening. Operating loss was $34.2 million in Q2 2026, compared with a $24.9 million loss in Q4 2025 and a $7.9 million loss in Q1 2024. Operating expenses reached $35.7 million, nearly seven times quarterly revenue.
Profitability deteriorated sequentially despite higher revenue. The gross margin fell to approximately 28.9% in Q2 2026 from 39.9% in Q1 2026 and 47.7% in Q2 2025. Selling, general and administrative expense rose to $28.9 million from $21.3 million sequentially, while research and development expense increased to $6.8 million.
Cash flow remains heavily negative. Net cash used in operating activities increased to $23.3 million in Q2 2026 from $17.8 million in Q1 2026 and $7.9 million in the restated Q2 2025. The company has reported negative operating cash flow in each of the supplied quarterly periods.
Debt and dilution have risen sharply. Short- and long-term debt totaled approximately $262.1 million at June 30, 2026, compared with about $22.2 million at March 31, 2024. Weighted-average basic shares increased from 44.6 million in Q1 2024 to 122.7 million in Q2 2026, creating meaningful dilution risk for existing shareholders.

ASP Isotopes’ financial profile reflects a company moving from an early-stage revenue base toward a larger operating platform. The substantial cash balance provides funding flexibility, but the company’s quarterly operating cash burn, rising expenses, sizable debt load and persistent net losses remain the key issues for investors. Sustained revenue growth, improving gross margins and a reduction in operating cash losses will be important indicators of whether the company can eventually support its expansion without additional debt or equity financing.

10/16/26 01:31 AM ETAI Generated. May Contain Errors.

ASP Isotopes Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ASP Isotopes' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ASP Isotopes' net income appears to be on a downward trend, with a most recent value of -$159.84 million in 2025, falling from -$4.95 million in 2022. The previous period was -$32.42 million in 2024. View ASP Isotopes' forecast to see where analysts expect ASP Isotopes to go next.

ASP Isotopes' total operating income in 2025 was -$59.91 million, based on the following breakdown:

Total Gross Profit: $3.41 million
Total Operating Expenses: $63.31 million

Over the last 3 years, ASP Isotopes' total revenue changed from $0.00 in 2022 to $23.85 million in 2025, a change of 2,384,900,000.0%.

In the past 11 quarters, ASP Isotopes' cash and equivalents has ranged from $2.29 million in Q3 2023 to $219.60 million in Q2 2026, and is currently $219.60 million as of their latest financial filing in Q2 2026.

ASP Isotopes had total debt of $212.21 million at the end of 2025, a 517.4% increase from 2024, and a 626,732.9% increase since 2022.

Over the last 3 years, ASP Isotopes' book value per share changed from 0.37 in 2022 to 1.84 in 2025, a change of 402.7%.

Related Companies

Financial statements for NASDAQ:ASPI last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ASP Isotopes (ASPI) Financials

Financials Breakdown Chart

Key Financial Trends

ASP Isotopes Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ASP Isotopes (ASPI) Financials

Annual Income Statements for ASP Isotopes

Quarterly Income Statements for ASP Isotopes

Annual Cash Flow Statements for ASP Isotopes

Quarterly Cash Flow Statements for ASP Isotopes

Annual Balance Sheets for ASP Isotopes

Quarterly Balance Sheets for ASP Isotopes

Annual Metrics And Ratios for ASP Isotopes

Quarterly Metrics And Ratios for ASP Isotopes

Financials Breakdown Chart

Key Financial Trends

ASP Isotopes Financials - Frequently Asked Questions

When does ASP Isotopes' fiscal year end?

How has ASP Isotopes' net income changed over the last 3 years?

What is ASP Isotopes' operating income?

How has ASP Isotopes' revenue changed over the last 3 years?

How much cash does ASP Isotopes have?

How much debt does ASP Isotopes have?

How has ASP Isotopes' book value per share changed over the last 3 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools